Clinical trials: Prostatic Neoplasms, completed
Metastatic Castration-Resistant Prostate Cancer
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
- Trial name
- CYCLONE 1 (NCT04408924)
- Testing
- Abemaciclib
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vitamin D and soy extract may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment.
- Trial name
- NCT00499408
- Testing
- Vitamin D, soy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Study of ES414 in Metastatic Castration-Resistant Prostate Cancer
The study will be conducted in 2 Stages. The primary objective of Stage 1 of the study is to identify the maximum tolerated dose (MTD) of ES414 administered intravenously to patients with mCRPC.
- Trial name
- NCT02262910
- Testing
- ES414
- Where
- 7 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Aptevo Therapeutics
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Prostate Cancer
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
- Trial name
- NCT00203424
- Testing
- Erlotinib + Bevacizumab
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Translational Oncology Research International
Prostatic Neoplasms, Prostate Cancer
18F-DCFBC PET/CT in Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer.
- Trial name
- NCT02190279
- Testing
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01120262
- Testing
- gene expression analysis, polymorphism analysis, laboratory biomarker analysis
- Volunteers
- 545 people
- Sponsor
- SWOG Cancer Research Network
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Prostate Cancer
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia
- Trial name
- NCT02274623
- Testing
- CTAP101 Capsules
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- OPKO Health, Inc.
Prostatic Neoplasms, Recurrence
PSMA PET/CT for Biochemical Recurrence Detection in Patients With Prostate Cancer
The aim of this study is to evaluate PSMA-PET for the detection of occult biological recurrence in patients with prostatic cancer referred to the Brest University Hospital.
- Trial name
- RB-PSMA (NCT04983459)
- Where
- France
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Prostate Cancer, Ultrasound Therapy
Evaluation of HIFU in TREATMENT OF LOCALIZED PROSTATE CANCER and OF RECURRENCE AFTER RADIOTHERAPY
to compare the efficacy of HIFU treatment with standard treatment in two situations: 1. as first-line cancer treatment, HIFU is compared to radical prostatectomy. 2.
- Trial name
- HIFI (NCT04307056)
- Testing
- Radical Prostatectomy, High Intensity Focused Ultrasound (HIFU) Treatment
- Where
- 49 sites in France, Guadeloupe
- Volunteers
- 3,862 people
- Sponsor
- Association Francaise d'Urologie
Prostate Cancer (Diagnosis), Quality of Life
Turkish Version of the UCLA Prostate Cancer Index
This study will evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the UCLA Prostate Cancer Index in men diagnosed with prostate cancer.
- Conditions
- Prostate Cancer (Diagnosis), Quality of Life, Reliability, Validity
- Trial name
- NCT07448545
- Testing
- Questionnaires
- Where
- Turkey (Türkiye)
- Volunteers
- 115 people
- Sponsor
- Lokman Hekim University
Prostate Cancer
Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects
Primary Goal The study's primary goal is to assess the safety of the BioProtect biodegradable balloon implant and implantation procedure, in prostate cancer subjects undergoing routine radiation therapy (XRT) treatment.
- Trial name
- NCT00918229
- Testing
- balloon implant, Balloon implantation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- BioProtect
Venous Thromboembolism (VTE)
Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners
Patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (VTE). VTE is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary…
- Trial name
- PRACTISE (NCT03965741)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban(Eliquis), Pradaxa (Dabigatran etexilate)
- Where
- Sweden
- Volunteers
- 97,765 people
- Sponsor
- Bayer
Prostate Cancer
Evaluation of Oncoxin-Viusid® in Prostate Cancer
A not randomized clinical survey was done in 25 pacients with histological diagnosis confirmed of a prostatic adenocarcinoma and hardy in hormonotherapy at the Calixto Garcia Hospital in Habana (2016-2018).
- Trial name
- NCT03543670
- Testing
- Oncoxin-Viusid
- Where
- Cuba
- Volunteers
- 25 people
- Sponsor
- Catalysis SL
Breast Cancer, Ovarian Cancer
OPTimizing Treatment Focused Genetic Testing IN Cancer
This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- OPT-IN (NCT04066361)
- Testing
- Chatbot, Video Education
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: SU5416 may stop the growth of prostate cancer by stopping blood flow to the tumor. Dexamethasone may be effective in slowing the growth of prostate cancer cells.
- Trial name
- NCT00006002
- Testing
- dexamethasone, semaxanib
- Where
- 18 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Prostate Cancer
PROState Cancer Patients Initiating Hormone Therapy: Effect of Exercise on CARDIOvascular Health (PROSCARDIO)
This study evaluates whether exercise can reduce treatment-related adverse effects in prostate cancer patients initiating androgen deprivation therapy.
- Trial name
- PROSCARDIO (NCT03776045)
- Testing
- Standard care plus exercise
- Volunteers
- 50 people
- Sponsor
- University of East Anglia
Prostate Cancer
Green Tea Extract and Prostate Cancer
The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression.
- Trial name
- NCT00676780
- Testing
- Polyphenon E (EGCG)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche